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ABSTRACT
The transcriptional profile induced by hypoxia plays important roles in the chondrogenic differ-
entiation of marrow stromal/stem cells (MSC) and is mediated by the hypoxia inducible factor
(HIF) complex. However, various compounds can also stabilize HIF’s oxygen-responsive element,
HIF-1a, at normoxia and mimic many hypoxia-induced cellular responses. Such compounds may
prove efficacious in cartilage tissue engineering, where microenvironmental cues may mediate
functional tissue formation. Here, we investigated three HIF-stabilizing compounds, which each
have distinct mechanisms of action, to understand how they differentially influenced the chon-
drogenesis of human bone marrow-derived MSC (hBM-MSC) in vitro. hBM-MSCs were
chondrogenically-induced in transforming growth factor-b3-containing media in the presence of
HIF-stabilizing compounds. HIF-1a stabilization was assessed by HIF-1a immunofluorescence
staining, expression of HIF target and articular chondrocyte specific genes by quantitative poly-
merase chain reaction, and cartilage-like extracellular matrix production by immunofluorescence
and histochemical staining. We demonstrate that all three compounds induced similar levels of
HIF-1a nuclear localization. However, while the 2-oxoglutarate analog dimethyloxalylglycine
(DMOG) promoted upregulation of a selection of HIF target genes, desferrioxamine (DFX) and
cobalt chloride (CoCl2), compounds that chelate or compete with divalent iron (Fe
21), respec-
tively, did not. Moreover, DMOG induced a more chondrogenic transcriptional profile, which
was abolished by Acriflavine, an inhibitor of HIF-1a-HIF-b binding, while the chondrogenic
effects of DFX and CoCl2 were more limited. Together, these data suggest that HIF-1a function
during hBM-MSC chondrogenesis may be regulated by mechanisms with a greater dependence
on 2-oxoglutarate than Fe21 availability. These results may have important implications for
understanding cartilage disease and developing targeted therapies for cartilage repair. STEM
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SIGNIFICANCE STATEMENT
The repair of damaged cartilage with engineered tissues may be hampered by challenges stem-
ming from the need to provide appropriate environmental cues to progenitor cells. By chemi-
cally targeting the hypoxia inducible factor (HIF) complex to mimic the effects of hypoxia, it is
shown that the 2-oxoglutarate (2-OG) analog dimethyloxalylglycine (DMOG) induces HIF signal-
ing and a more articular chondrocyte-like expression profile in human bone marrow-derived
mesenchymal stem cells (BM-MSC) compared with cobalt chloride or desferrioxamine, which
reduce divalent iron (Fe21) bioavailability. These observations suggest that human BM-MSC
may rely more on mechanisms that utilize 2-OG than Fe21 during chondrogenesis and suggest
that DMOG could be effective therapeutically for cartilage regeneration.
INTRODUCTION
Acute lesions to the articular cartilage that do
not heal may be painful and can progress to
osteoarthritis. Conventional treatments such as
microfracture or articular chondrocyte implan-
tation are not always effective in mediating
repair [1, 2]. Tissue engineering strategies that
combine cells with bioactive factors and
biomaterial scaffolds may allow for de novo
articular cartilage formation and provide an
alternative therapy for patients [3–5]. How-
ever, the provision of cues that can appropri-
ately direct progenitor cell differentiation and
tissue formation remain a challenge.
One of the regulatory factors controlling
articular cartilage development is the cellular
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response to physiological hypoxia [6, 7]. The cellular response
to hypoxia is mediated by the hypoxia inducible factor [8]
pathway which induces expression of hypoxia-responsive
genes [9]. At normoxia, the hypoxia inducible factor (HIF)
complex is unable to recruit the oxygen-responsive HIF-1a
subunit, which inhibits expression of genes containing a HIF
response element within their promoter regions [10]. Under
hypoxic conditions, HIF-1a translocates to the nucleus where
it complexes with other components of the HIF complex to
initiate transcription of HIF target genes [10]. HIF-1a is central
in the formation of articular cartilage during development [6,
7]. It also plays essential roles in the differentiation of mesen-
chymal stem/stromal cells (MSC) [11, 12] and chondroprogeni-
tors [13] into cells capable of producing cartilage-like
extracellular matrix (ECM) [14–16]. Moreover, HIF-1a is vital
in maintaining the articular phenotype of differentiated chon-
drocytes and inhibiting hypertrophic differentiation [17].
Two hydroxylases, prolyl hydroxylase 2 (PHD2) and factor
inhibiting HIF (FIH), regulate the participation of HIF-1a in the
HIF complex [18, 19]. Each catalyzes the hydroxylation of spe-
cific residues on HIF-1a by utilizing molecular oxygen (O2) as a
substrate together with ascorbic acid, iron (Fe21) and 2-
oxoglutarate (2-OG). PHD2-mediated proline hydroxylation
results in ubiquitination of HIF-1a and its subsequent proteaso-
mal degradation, whereas asparagine hydroxylation by FIH pre-
vents HIF-1a from binding to the co-factor, p300 in the HIF
complex [18]. Under hypoxic conditions, the lack of oxygen
reduces PHD2 and FIH activity, enabling HIF-1a to accumulate
in the nucleus and form an active transcriptional complex with
co-factors at the promoter regions of HIF target genes.
The importance of hypoxia and HIF in cartilage develop-
ment and maintenance point toward its potential utility in
cartilage tissue engineering strategies. Indeed, chemical
agents that upregulate HIF have been shown to drive the
chondrogenic differentiation of MSC and promote articular
chondrocytes to produce a cartilage-like ECM [12, 20, 21].
However, studies which compare the efficacy of different HIF-
stimulating compounds in driving the chondrogenesis of
human bone marrow-derived mesenchymal stem cells (hBM-
MSC) compared with standard protocols which utilize trans-
forming growth factor-b (TGF-b), are lacking.
Therefore, we compared the effects of three hydroxylase
inhibitors on the chondrogenic differentiation of hBM-MSC.
Dimethyloxalylglycine (DMOG) strongly binds to the 2-OG
binding pocket of both FIH and PHD2, acting as a competitive
inhibitor [22]; desferrioxamine (DFX) sequesters intracellular
Fe21, which is required by FIH and PHD2 [23], and thereby
reduces their activity; and cobalt chloride (CoCl2) competes
with Fe21 by directly binding to the PHD2 active site [24]. We
chose these agents because they cover the main classes of
HIF-stimulating compounds, and as such, upregulate HIF-1a
via distinct mechanisms (Fig. 1A, 1B). These compounds are
also the most widely studied for chemically regulating HIF and
may shed light on key regulatory elements of hypoxic signal-
ing during chondrogenesis. Moreover, investigating the PHD2/
FIH inhibitors during hBM-MSC chondrogenesis may aid our
understanding of the pathophysiology of degenerative dis-
eases such as osteoarthritis [8], for which HIF-1a is known to
play a protective role [25].
Here, we show that while CoCl2, DFX, and DMOG all
induce similar levels of HIF-1a stabilization, only DMOG
strongly enhances HIF-mediated transcription of key chondro-
genic genes. Nevertheless, DMOG negatively impacted the
production of Collagen Type II and glycosaminoglycans
(GAGs), which could be alleviated by only exposing cells to
the compound during the latter stages of chondrogenesis.
Together, these observations highlight the potential impor-
tance of mechanisms which utilize 2-OG compared with Fe21
for the transcriptional control of HIF target genes during
hBM-MSC chondrogenesis. They also suggest that 2-OG inhibi-
tors may better promote a chondrogenic transcriptome com-
pared with either DFX or CoCl2. These observations may
inform on improved, targeted strategies for stimulating carti-
lage ECM formation in tissue engineering-based therapies.
MATERIALS AND METHODS
Isolation and Expansion of hBM-MSC
hBM-MSCs were isolated from bone marrow aspirates collected
from the iliac crest of healthy pediatric donors, with informed
consent from their parents or guardians. Cells were seeded in
CellSTACK (Corning, Sigma Aldrich, UK) culture chambers at 10–
25 3 106/636 cm2 and cultured in aMEM supplemented with
human platelet lysate (Stemulate, Cook Medical, USA). At 90%–
100% confluency, cells were passaged and seeded at 5,000 cells
per cm2. For immunophenotyping of hBM-MSCs, the following
antibodies were used in conjunction with a FACSCalibur analyzer
(BD Biosciences, UK): CD90-FITC, CD105-APC, CD73-PE, CD34-
PE, and CD45-FITC (all from BD Biosciences). All human tissue
was approved for use by the UK National Research Ethics Service
(12/WA/0196) and was collected by the National Institute for
Health Research, which is supported by the Imperial College
Healthcare Tissue Bank (HTA license 12275). Cultures were
found to express CD90, CD105, CD73 and not express hemato-
poietic markers CD34 and CD45 [26] (data not shown). hBM-
MSCs were expanded in growth media (GM; aMEM1 10% fetal
bovine serum [FBS], Thermo Fisher Scientific, UK) under stan-
dard conditions (5% CO2).
Chondrogenic Induction of hBM-MSC
hBM-MSCs were expanded to passage 5 in GM under standard
culture conditions before cryopreservation in a solution com-
posed of 10% dimethyl sulfoxide, Sigma-Aldrich, 40% FBS, and
50% GM. Cells were stored in liquid nitrogen prior to use. For
chondrogenic induction experiments, cryovials of hBM-MSCs
were thawed in GM and grown to confluence before plating at
3 3 104/cm2 into multi-well tissue culture plates. Cultures were
incubated for 24 hours in GM prior to induction using standard
chondrogenic differentiation media (CDM). See Figure 1C for
experimental plan. Cells were differentiated as monolayers to
prevent the formation of a local hypoxic microenvironment
independent of experimental conditions (physiological or chem-
ically induced hypoxia). Indeed, while pellet/micromass cultures
may be more conducive for chondrogenesis, the bioavailability
of oxygen may vary between cells at the periphery and center
of such cultures. CDM consisted of High Glucose Dulbecco’s
modified Eagle medium (Sigma-Aldrich)1 2 mM L-Glutamine
(Thermo Fisher Scientific)1 100 nM Dexamethasome (Sigma-
Aldrich)1 1% Insulin, Transferrin, Selenium Solution (Thermo
Fisher Scientific)1 1% Antibiotic Antimycotic solution (Sigma-
Aldrich)1 50 lg/ml Ascorbic acid-2-phosphate (Sigma-
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Aldrich)1 40 lg/ml L-proline (Sigma Aldrich)1 10 ng/ml TGF-
b3 (Peprotech). CDM was supplemented with HIF-stabilizing
compounds (Sigma-Aldrich): 100 lM CoCl2, 50 lM DFX, and 200
lM DMOG, or incubated in un-supplemented CDM at hypoxia
(5%O2) or normoxia. To achieve HIF-1a inhibition, media was
further supplemented with 500 nM Acriflavine (ACF; Santa Cruz
Biotechnology, USA).
Neutral Red Viability Assay
Neutral red dye (Sigma-Aldrich) dissolved in cell culture medium
was incubated with differentiating hBM-MSC for 2 hours before
fixation in 0.1% Calcium Chloride1 0.5% paraformaldehyde
(both from Sigma-Aldrich). Dye retained by hBM-MSC was solu-
bilized in 1% acetic acid1 50% ethanol (both from Sigma-
Aldrich). Quantification of solubilized Neutral Red was then per-
formed on an absorbance spectrophotometer at 540 nm.
PicoGreen Assay
Samples were snap-frozen at 2808C and digested in 400 lg/
ml Papain Buffer at 658C for 18 hours. Double stranded deox-
yribonucleic acid (dsDNA) content in papain-digested cultures
was quantified using a PicoGreen kit (Thermo Fisher
Figure 1. Schematics highlighting the role of hydroxylase inhibitors in regulation of HIF-1a-mediated transcription and the study exper-
imental design. (A): Under hypoxic conditions, HIF-1a forms an active transcription complex with HIF-1b and co-factors such as CBP/
p300. This HIF complex then binds to the promoter regions of target genes at the HIF-response element sites, inducing transcription.
(B): At normoxia, two hydroxylases—PHD2 and FIH, utilize oxygen and other substrates to hydroxylate HIF-1a which promotes its degra-
dation and inhibits binding by CBP/p300. Here, we aimed to stabilize HIF-1a at normoxia by inhibiting the hydroxylases with CoCl2, DFX
or DMOG. (C): Experiment design. To produce each biological replicate, hBM-MSCs were thawed and expanded to passage 5 before re-
seeding at a density of 3 3 104 cell per cm2 in multi-well plates. Each well or set of wells was assigned to a specific condition: 20%O2,
20%O21CoCl2, 20%O21DFX, 20%O21DMOG, or 5%O2. Separate experiments included each HIF-stabilizing compound in the presence or
absence of ACF, and a comparison of late with constitutive exposure. In each condition, cultures were chondrogenically differentiated
before assays at the time points specified in the legend of each figure. Abbreviations: ACF, Acriflavine; CoCl2, cobalt chloride; DFX, des-
ferrioxamine; DMOG, dimethyloxalylglycine; ECM, extracellular matrix; FIH, factor inhibiting hypoxia inducible factor; hBM-MSCs, human
bone marrow-derived mesenchymal stem cells; HIF, hypoxia inducible factor; PHD2, prolyl hydroxylase 2.
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Scientific). A linear relationship was observed between hBM-
MSC number and dsDNA content.
Sodium Dodecyl Sulfate-PAGE and Western Blotting
Following 24-hours of culture, cells were lysed in sodium
dodecyl sulfate (SDS) buffer and protein was quantified using
a Bicinchoninic Acid assay (Thermo Fisher Scientific). Lysates
were run on polyacrylmide gels (Biorad, UK) and transferred
using the Trans-Blot Turbo Transfer System (Biorad). HIF-1a
and housekeeping protein b-Actin were bound by primary
antibodies (H-206; Santa Cruz Biotechnology and ab8227;
Abcam, UK). Signal detection produced between a horseradish
peroxidase-conjugated secondary antibody (sc-2004; Santa
Cruz) and the Chemiluminescent ECL substrate (Biorad) were
detected on a Chemidoc Touch imaging platform (Biorad).
HIF-1a and protein levels were generated by densitometric
analysis with ImageJ and normalized to that of b-Actin.
Quantitative Polymerase Chain Reaction
RNA was extracted using the RNeasy Mini Kit (Qiagen, DE).
Hundred nanograms of RNA per sample was reverse tran-
scribed using M-MLV Reverse Transcriptase (Promega, UK) and
cDNA was amplified using quantitative polymerase chain reac-
tions (qPCR) in a CFX384 (Biorad). Brilliant III Ultra-Fast SYBR
Green QPCR Master Mix (Agilent, USA) was used in conjunc-
tion with primers specific to genes of interest. Primer sequen-
ces are shown in Supporting Information Table S1. All primers
produced a linear relationship between template concentra-
tion and Ct value. Reaction efficiencies were confirmed to lie
between 90 and 110%. Raw Ct values were converted to tran-
script copy number by the relative standard curve method of
analysis, and expression levels were normalized to that of
RPL13A. Following normalization to the housekeeping gene,
expression levels were then normalized to that of the
untreated control to determine fold change in expression
induced by each treatment.
Immunofluorescence Staining
Cultures were fixed in 4% (wt/vol) paraformaldehyde for 15
minutes. HIF-1a and Collagen Type II were then detected
using H-206 (Santa Cruz) and ab34712 (Abcam), respectively,
overnight, following blocking with (10%) goat serum (Sigma-
Aldrich) for 60 minutes and permeabilization in 0.1% (vol/vol)
Triton X-100 solution (Sigma Aldrich) for 60 minutes, both at
room temperature (RT). Collagen Type X was detected using
ab49945 (Abcam) at a 1:250 dilution overnight. Rabbit-
derived primary antibodies were visualized with ab150077
(Abcam) after staining for 60 minutes at RT at dilutions of
1:100 and 1:200 for Collagen Type II and HIF-1a, respectively.
Mouse-derived primary antibodies were detected with biotin
(ab6788, Abcam) and Streptavidin (S11223, Thermo Fisher Sci-
entific) both at 1:350 for 60 minutes. Cultures were counter-
stained with 0.1 lg/ml DAPI for 60 minutes to visualize nuclei
and fluorescence was imaged on an Axiovert200M microscope
(Zeiss, DE). The images in Supporting Information Figure S1
confirm that signal was due to each primary antibody and not
background fluorescence or nonspecific binding of the second-
ary antibody.
Alcian Blue Staining
Cultures fixed in 4% paraformaldehyde were stained with 1%
Alcian blue solution, pH 1.0 (Sigma-Aldrich) prepared in 0.1N
HCl. Hematoxylin (Vector Laboratories, UK) was used to visual-
ize cell nuclei and staining was imaged on an Axiovert200M
microscope (Zeiss).
Glycosaminoglycan Quantification
At day 21 of chondrogenesis, cultures were washed in phos-
phate buffered saline and frozen at 2808C before their diges-
tion in 400 lg/ml Papain buffer (Sigma-Aldrich) supplemented
with 0.2M Sodium Phosphate1 5 mM Ethylenediaminetetra-
acetic acid1 5 mM L-Cysteine (all Sigma-Aldrich) at 658C for
18 hours. GAGs were quantified from Papain-digested lysates
using a Blyscan GAG assay kit (Biocolor, UK) in which GAGs
were dyed with 1,9-dimethyl-methylene blue and subse-
quently dissociated with Propan-1-ol solution before quantifi-
cation on an absorbance spectrophotometer at 640 nm.
Values were normalized to levels of dsDNA, which were quan-
tified using the PicoGreen assay.
Immunofluorescence Quantification
Immunofluorescence images were captured using identical
gain, exposure, and offset for all conditions in each experi-
ment. These were determined with positive controls that
expressed the antigen of interest, and negative controls in
which the primary antibody was omitted (Supporting Informa-
tion Fig. S1). The same threshold fluorescence intensity for
images of all conditions within an experiment was set, below
which the signal produced was negated as background. The
signal produced above the threshold was regarded as bona
fide protein detection and was used to create a binary repre-
sentation of each image. The percentage of immunofluores-
cence staining present within a specified area was then
determined.
Statistical Analysis
All statistical analyses were performed in Prism7 (GraphPad,
USA) with the Mann-Whitney test used to compare two con-
ditions and Kruskal-Wallis with Dunn’s Correction for multiple
condition comparisons. Nonparametric tests were used as we
were unable to demonstrate normality in all datasets. *marks
all differences that were statistically significant (p< .05).
RESULTS
Hypoxia Promotes HIF Stabilization and a More
Articular Cartilage-Like Cell Phenotype
It is well established that hBM-MSCs can be chondrogenically
differentiated with transforming growth factor b3 (TGF-b3)
ligands. Therefore, we first aimed to determine if chondrogen-
esis could be further enhanced by culture under hypoxic con-
ditions, as previously reported [11]. Hypoxia increased
expression of a selection of known HIF target genes including
VEGFA, EGLN, and PGK1 (all p 5 .0286) [27–29] compared
with that in hBM-MSC cultured under normoxic conditions
(Fig. 2A). These observations were in line with previous stud-
ies which have similarly shown a rapid (24 hours) upregula-
tion of HIF and HIF-mediated transcription in response to
4 HIF-1a-Stabilizing Agents for Chondrogenesis
VC 2018 The Authors STEM CELLS
STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
Taheem, Foyt, Loaiza et al. 1383
www.StemCells.c m © 2018 The Authors STEMCELLS published byWiley Periodicals, Inc. on behalf of AlphaMed Press
hypoxia under chondrogenic conditions [11]. However, 5%O2
did not significantly affect expression of SOX9 (Fig. 2A, 2B;
p5 .1), the master transcriptional regulator of chondrogenesis
[30], after either 1 or 14 days in culture.
At day 14, we observed upregulation of expression of the
gene for the articular cartilage ECM component Collagen Type
II (COL2A1, p 5 .0002), and downregulation of the hypertro-
phic marker Collagen Type X [31] (COL10A1, p 5 .0006) under
Figure 2. Hypoxia induces HIF-1a nuclear localization and promotes an articular chondrocyte-like phenotype. (A, B): gene expression
of VEGFA, EGLN and PGK1, and SOX9 (n5 4) at day 1 (A) and SOX9, COL2A1, and COL10A1 (n5 8) at day 14 of chondrogenesis (B). Val-
ues plotted are fold change in response to 5%O2 compared with 20%O2, which is represented by the horizontal dotted line. The solid
gray line represents the mean. *denotes p< .05 compared with 20%O2. (C): Human bone marrow-derived mesenchymal stem cells num-
ber throughout chondrogenesis as determined by PicoGreen assay (n5 3). Values are normalized to cell number at day 0 and error bars
show standard error of the mean. (D): Quantification of nuclear HIF-1a immunofluorescence in (F–H) at day 1 of chondrogenesis
(n5 3). Each value represents the percentage of a single nucleus that is occupied by HIF-1a. The red horizontal line represents the
mean with *p< .05 compared with 20%O2. (E–H) HIF-1a immunofluorescent staining. Scale bar5 50 lm. Representative images of 3
independent repeats. Images were cropped and magnified to visualize localization of HIF-1a. (I, J): Alcian blue staining for GAGs with
hematoxylin counterstain at day 21 of chondrogenesis (n5 3). Scale bar5 400 lm. (K–N): Collagen Type II (K, L) and X (M, N) immuno-
fluorescence staining at day 21 of chondrogenesis (n5 3). Scale bar5 400 lm. Brightness and contrast were adjusted to an equal
degree between all conditions. Abbreviations: GAGs, glycosaminoglycans; HIF, hypoxia inducible factor.
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hypoxic conditions compared with that at normoxia (Fig. 2B).
COL2A1 and COL10A1 are targets of transcription factors
SOX9 and RUNX2, respectively, and are known to be regulated
as the chondrogenic differentiation of MSC proceeds [11]. Cul-
ture for 21 days under hypoxic conditions did not affect cell
viability or proliferation (Fig. 2C). However, as expected, we
did observe increased HIF-1a nuclear localization (p < .0001)
in hypoxic compared with normoxic cultures (Fig. 2D–2H).
Hypoxia also increased Alcian Blue staining of GAGs (Fig. 2I,
2J), but did not affect the immuno-detection of Collagen Type
II protein (Fig. 2K, 2L). Nevertheless, we did detect a decrease
in staining for Collagen Type X (Fig. 2M, 2N), consistent with
hypoxia’s inhibitory role to chondrocyte hypertrophy [17].
Together, these observations confirmed that culture under
hypoxic conditions in the presence of TGF-b3 promoted an
articular chondrocyte-like phenotype that was conducive for
articular cartilage ECM rather than hypertrophic cartilage for-
mation. This effect appeared to not require a corresponding
upregulation of SOX9, but instead correlated with increased
immunostaining for HIF-1a, upregulation of select HIF target
genes VEGFA, EGLN, and PGK1, and increased HIF-1a nuclear
localization.
CoCl2, DFX, and DMOG Induce HIF-1a Localization, but
Only DMOG Strongly Upregulates HIF Targets VEGFA,
PGK1, and ELGN
Having determined that hypoxia promoted HIF-1a stabilization
and expression of VEGFA, EGLN, and PGK1, we next aimed to
determine if inhibitors of the hydroxylases PHD2 and FIH
would have a similar effect on hBM-MSC cultured under nor-
moxic conditions. We first determined appropriate doses for
the hydroxylase inhibitors DMOG, DFX, and CoCl2 by confirm-
ing that concentrations of each used extensively in the litera-
ture [22, 24, 32–34] were nontoxic to hBM-MSC over 21 days
of chondrogenic differentiation (Supporting Information Figs.
S2, S3). Next, we confirmed that each could stabilize HIF by
carrying out Western blots for HIF-1a in whole-cell lysates
after 24 hours, as HIF is known to be rapidly induced in
response to PHD2/FIH inhibition [22]. Levels of HIF-1a protein
were significantly increased in cells cultured under hypoxic
conditions (p 5 .0286); however, despite trends for increased
levels of HIF-1a after treatment with HIF stabilizing com-
pounds, we failed to detect statistically significant differences
(p 5 .314) compared with controls (Fig. 3A, 3B). Nonetheless,
nuclear localization of HIF-1a was enhanced compared with
controls (p .0001) in response to treatment with all three
compounds (Fig. 3C–3K).
We then examined the effects of the hydroxylase inhibi-
tors on HIF target gene expression. DMOG significantly and
consistently upregulated expression of VEGFA (p 5 day 1:
.0073, day 7: .0470, day 21: .0005), PGK1 (p 5 day 1: .0073,
day 7: .0013, day 14: .0013, day 21: .0031), and EGLN (p 5
day 1: .0108, day 7: .0332, day 14: .0470, day 21: .0005) (Fig.
3L–3N). However, the effects of CoCl2 and DFX were more
subtle, and we only observed upregulation of PGK1 expression
at day 14 (p5 .0391) and EGLN at day 21 (p 5 .0396) in
response to DFX. These observations show that while CoCl2,
DFX, and DMOG all affect HIF-1a stabilization, only DMOG
strongly upregulated expression of a selection of HIF target
genes. This suggests that DMOG more potently enhanced HIF
activity compared with DFX or CoCl2.
DMOG Stimulates hBM-MSC to Adopt an Articular
Chondrocyte-Like Transcriptional Profile
As all HIF mimetics stabilized HIF-1a and DMOG also upregu-
lated expression of HIF target genes, we next investigated the
effect of these compounds on chondrogenic gene expression.
DMOG treatment upregulated SOX9 gene expression after 7
(p5 .0159) and 21 (p5 .0332) days in culture (Fig. 4A), while
RUNX2, a key regulator of osteogenesis [35], was unaffected
under all conditions (Fig. 4B). This resulted in a DMOG-
mediated increase in the SOX9 to RUNX2 expression ratio
throughout differentiation (Fig. 4C; p 5 day 7: .0192, day 14:
.0398, day 21: .0159). All inhibitors upregulated expression of
COL2A1 (Fig. 4D; p5 CoCl2: .0280, DFX: .0180, DMOG: .0008)
with DMOG significantly downregulating COL10A1 (Fig. 4E;
p5 .0037) leading to an increased COL2A1/COL10A1 mRNA
ratio due to DFX and DMOG (Fig. 4F; p5DFX: .0259, DMOG:
<.0001). ACAN, which encodes the gene for Aggrecan, the
most abundant proteoglycan in cartilage [36], was not upregu-
lated by any treatment (Fig. 4G); and MMP13, whose product
contributes to an osteoarthritic chondrocyte phenotype [37],
was similarly unaffected (Fig. 4H). The articular cartilage phe-
notype is marked by appropriate post-translational modifica-
tions of secreted collagen by enzymes encoded by P4HA1 and
LOX [14, 15]. DMOG strongly upregulated both P4HA1 (Fig. 4I;
p5 .0039) and LOX (Fig. 4J; p5 .0027) expression, while DFX
only upregulated LOX (p5 .0056) and CoCl2 had no significant
effects. Taken together, these observations demonstrate that
DMOG upregulated transcriptional regulators of chondrogene-
sis and genes involved in cartilage ECM formation, while the
effects of CoCl2 and DFX were more limited.
DMOG Inhibits Incorporation of Collagen Type II, Type
X, and GAGs into the Cell-Secreted ECM
As treatment with DMOG regulated the expression of genes
associated with a chondrocyte phenotype, we next asked if
this influenced cartilage-like matrix formation. In line with
changes in gene expression, hBM-MSC treated with DMOG
for 21 days showed little to no staining for Collagen Type X
compared with controls (Fig. 5A, 5D). We observed a similar
effect in both DFX- and CoCl2-treated cultures (Fig. 5B, 5C).
However, while CoCl2- and DFX-treated cultures showed simi-
lar levels of staining for Collagen Type II as controls (Fig. 5E–
5G), DMOG-treated cultures showed only sparse staining (Fig.
5H). This was confirmed by quantification of Collagen Type II
immunofluorescence both without (p5 .0286) and with nor-
malization to cell number which indicated reduced Collagen
Type II production per cell (Fig. 5M; p5 .0286). Alcian blue
staining confirmed these observations as DMOG-treated cul-
tures showed fewer GAG-positive areas than the other
groups, although quantitative differences in staining on a per
cell basis were not significant (Fig. 5I–5L, 5N). Overall, DMOG
appeared to reduce the total amount of cartilage-like ECM
that cells formed in their immediate extracellular space.
HIF-1a Mediates DMOG’s Induction of an Articular
Chondrocyte Transcriptional Profile
As DMOG mediated antithetical effects in terms of chondro-
genic transcriptional profile and ECM formation, we next
aimed to study its mechanism of action. To accomplish this,
we supplemented CoCl2/DFX/DMOG-containing CDM with
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Acriflavine (ACF), an inhibitor of HIF-1a and HIF-1b binding
[38]. ACF abolished the DMOG-induced upregulation of estab-
lished HIF targets, but did not affect total cell number during
chondrogenesis (Supporting Information Fig. S4A, S4B). Stain-
ing for Collagen Type II in DMOG-treated cultures supple-
mented with ACF remained sparse (Fig. 6A–6C), but
quantitative image analyses showed staining on a per cell
basis was no different from controls, while cultures treated
with DMOG alone were significantly lower (Fig. 6D;
p5 .0076). This suggests that the inhibitory role of DMOG on
Collagen Type II matrix formation may be partly mediated
through HIF-1a activity.
We next asked if DMOG’s stimulation of the chondrogenic
transcription profile in hBM-MSC was also mediated through
HIF-1a. ACF abrogated DMOG-mediated changes in expression
of HIF targets, VEGFA (Fig. 6E; p5 -ACF: .0132, 1ACF: .0772)
and EGLN (Fig. 6F; p5 -ACF: .0073, 1ACF: 0.1232), COL2A1
(Fig. 6H; p5 -ACF: .0286, 1ACF: >.999), COL10A1 (Fig. 6I;
p5 -ACF: .002, 1ACF: >.3277), the COL2A1/COL10A1 ratio
(Fig. 6J; p5 -ACF: .0031, 1ACF: >05998), and showed a
Figure 3. CoCl2, DFX, and DMOG increase nuclear localization of HIF-1a but only DMOG induces stable upregulation of HIF targets. (A,
B): Detection of HIF-1a and housekeeping protein, b-Actin by Western Blot analysis of whole-cell lysates from hBM-MSCs at day 1 of
chondrogenesis (A; n5 4). Western blots were quantified and normalized to levels of b-Actin (B; n5 4). Values are magnitude difference
compared with the no treatment control, which is represented by the horizontal dotted line. Solid colored lines are the mean for each
condition. (C): Quantification of nuclear HIF-1a immunofluorescence at day 1 of chondrogenesis (n5 4). Each value represents the per-
centage of a single nucleus that is occupied by HIF-1a. The red horizontal line represents the mean and *p< .05 compared with 20%O2.
(D–K): HIF-1a immunofluorescence staining at day 1 of chondrogenesis (n5 4). Scale bar5 50 lm. Images were cropped and magnified
to visualize localization of HIF-1a. Brightness and contrast were adjusted to an equal degree between all conditions. (L–N): Gene expres-
sion of VEGFA, PGK1, and EGLN due to CoCl2, DFX, DMOG, and 5%O2 (n5 4). Values are fold change compared with the no treatment
control represented by the horizontal dotted line. Solid colored lines represent the mean for each condition. *p< .05 compared with
20%O2 at the same time point. Abbreviations: CoCl2, cobalt chloride; DFX, desferrioxamine, DMOG, dimethyloxalylglycine; HIF, hypoxia
inducible factor.
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similar trend for SOX9 expression (Fig. 6G; p5 -ACF: .0772,
1ACF: .5348) Interestingly, despite a lack of upregulation of
SOX9 under hypoxic conditions, we observed a negative effect
of hypoxia on SOX9 expression in the presence of ACF (Fig.
6G; p5 .0286). This is consistent with the observation that
ACF reduced the ratio of COL2A1/COL10A1 under hypoxic
conditions (Fig. 6J; p5 .0286) and suggests that hypoxia, via
HIF-1a, does indeed regulate basal levels of chondrogenic tar-
gets genes, such as SOX9. Overall, these data suggest that
HIF-1a mediated DMOG’s effect on the transcriptional profile
of chondrogenically induced hBM-MSC. Moreover, ACF
appeared to have a larger effect on DMOG-mediated tran-
scription than that induced by either CoCl2 or DFX (Supporting
Information Fig. S4C–S4J).
Late DMOG Treatment Enhances Chondrogenesis
As DMOG upregulated chondrogenic transcripts but continu-
ous treatment led to reduced staining for cartilage-like matrix,
we next asked if altering either the length/timing of treat-
ment would influence ECM formation. Therefore, we next
treated hBM-MSC with DMOG, DFX, and CoCl2 either continu-
ously (as before) or during late (days 14–21) time periods and
analyzed mRNA and protein expression of ECM markers after
21 days. Late DMOG treatment did not negatively affect the
secretion of Collagen Type II compared with controls
(p5 .282), as we observed with continuous DMOG treatment
(p5 .0188). This contrasted with treatment with either DFX or
CoCl2, where both continuous and late treatment had no
effect on Collagen Type II secretion (p .9999 for both, Fig.
7A–7H). At the gene expression level, like continuous
treatment (p5 .0023), late exposure to DMOG induced signifi-
cant upregulation of SOX9 (Fig. 7I; p5 .0168). Late DMOG also
upregulated expression of P4HA1 (Fig. 7J; p5 .0286), and HIF
targets VEGFA (p5 .0358, Fig. 7K) and EGLN (p5 .0208, Fig. 7L)
as with continuous DMOG treatment (p5 P4HA1: .0313, VEGFA:
.0118, EGLN: .0088). In contrast, neither continuous nor late
CoCl2 and DFX treatment significantly affected the expression of
these genes, with the exception of continuous DFX treatment on
SOX9 (p5 .0286; Fig. 7I) and P4HA1 (p5 .0286; Fig. 7J). Taken
together, late treatment with DMOG induced a similar expres-
sion profile to continuous treatment, but without negatively
impacting the formation of cartilage-like ECM.
DISCUSSION
Hypoxic conditions are known to favor articular cartilage
development. The pro-chondrogenic effects of hypoxia are
thought to be mediated primarily through HIF-1a via the for-
mation of a transcriptionally-active complex at target genes
[7, 12]. Therefore, we and others hypothesized that com-
pounds that increase HIF-1a availability would promote HIF-
mediated chondrogenesis. Previous studies have examined
the effect of CoCl2 [12], DFX [39], and DMOG [21, 40] in this
context. While such studies have cemented the role of HIF-1a
in chondrogenesis, to our knowledge no study has yet exam-
ined their comparative effects during cartilage formation or
the chondrogenic differentiation of precursors. As the inhibi-
tors have differential mechanisms of action, comparatively
studying their effects may have important implications for HIF
biology and cartilage regenerative medicine. Indeed, instead
Figure 4. DMOG induces a chondrogenic transcriptional profile and inhibits markers of osteoblastic and hypertrophic differentiation
but also reduces the formation of a cartilage-like ECM. (A–J): Gene expression of SOX9 (A; n5 4), RUNX2 (B; n5 4) and SOX9/RUNX2
(C; n5 4), COL2A1 (D; n5 7), COL10A1 (E; n5 7), COL2A1/COL10A1 (F; n5 7), ACAN (G; n5 4), MMP13 (H; n5 7), P4HA1 (I; n5 4),
and LOX (J; n5 7) throughout chondrogenesis due to treatment with CoCl2, DFX, DMOG, and 5%O2. Values are fold change compared
with the no-treatment control represented by the horizontal dotted line. Solid colored lines are the mean for each condition. *p< .05
compared with 20%O2 at the same time point. Abbreviations: CoCl2, cobalt chloride; DFX, desferrioxamine, DMOG,
dimethyloxalylglycine.
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of utilizing physiological hypoxia for regenerative medicine,
stabilizing the HIF complex under normoxic conditions would
remove the complex logistics required for spatial organization
of oxygen. This may be particularly valuable in engineering
constructs for the repair of full osteochondral defects due to
the contrasting oxygen requirements of avascular cartilage
and vascularized bone [6]. HIF mimetics could also potentially
avoid the undesirable HIF-independent effects of hypoxia such
as the unfolded protein response and associated cell stress
[41], and could preclude the development of a tolerance to
the reduced oxygen levels [42, 43].
In our control conditions, we defined hypoxia as 5%O2 to
balance its well-described pro-chondrogenic effects against its
negative impacts on cell viability [44]. As expected, after 24
hours in culture under hypoxic conditions, we detected upre-
gulation of HIF target genes, as others have described [19,
45], as well as increased expression of SOX9 target COL2A1
and downregulation COL10A1 (day 14). We also detected an
increase in staining for GAGs and reduced Collagen Type X
protein formation. Surprisingly, upregulation of SOX9 was not
maintained throughout the 21-day differentiation. This is in
keeping with previous reports that continued upregulation of
SOX9 expression in mouse MSC under hypoxic conditions
does not correlate with upregulation of its target genes [11].
We also observed that SOX9 expression was downregulated in
the presence of ACF, perhaps suggesting that hBM-MSC cul-
tures do rely on HIF for physiological hypoxia’s downstream
effects. Indeed, cells may develop a tolerance to hypoxia fol-
lowing the initial induction [43], and during long-term culture,
hypoxia may act to maintain basal levels of expression of
chondrogenic genes.
One of our most striking observations was the ability of
DMOG, via HIF-1a, to induce hBM-MSC to upregulate expres-
sion of HIF target genes and chondrogenic transcripts, and
downregulate mRNA encoding hypertrophic chondrocyte
markers such as Collagen Type X. In comparison, neither
Figure 5. DMOG reduces the formation of a cartilage-like ECM. (A–H): Collagen Type X (A–D) and II (E–H) immunofluorescence staining
at day 21 of chondrogenesis (n5 3). Scale bar5 400 lm. Brightness and contrast were adjusted to an equal degree between all condi-
tions. (I–L): Alcian blue staining for GAGs with hematoxylin counterstain at day 21 of chondrogenesis (n5 3). Scale bar5 400 lm. (M,
N): Quantification of Collagen Type II immunofluorescence (M) and glycosaminoglycans (N) at day 21 of chondrogenesis (n5 4) without
and with normalization to DAPI-immunofluorescence/double-stranded DNA. Values are fold change compared with the no-treatment
control represented by the horizontal dotted line. Solid colored lines represent means for each condition. *p< .05 compared with
20%O2. Abbreviations: CoCl2, cobalt chloride; DFX, desferrioxamine, DMOG, dimethyloxalylglycine; GAGs, glycosaminoglycans.
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CoCl2 nor DFX stimulated similar changes, despite their ability
to promote HIF-1a nuclear localization. The stability and
nuclear localization of HIF-1a is controlled by PHD2, whereas
HIF-1a co-factor binding is controlled by FIH; DMOG has been
shown to inhibit both hydroxylases [22]. This is unlike the
effect of iron chelators which target PHD2, but do not inhibit
FIH as potently [24]. Others have shown that FIH requires
higher levels of 2-OG than PHD2 to achieve the same levels
of enzymatic activity [46], which may suggest an increased
sensitivity of FIH than PHD2 to inhibition by 2-OG analogs.
HIF-1a activity in hBM-MSC may also be more dependent on
FIH inhibition, rather than PHD2, as high levels of HIF-1a
mRNA have been observed in these cells [42]. Indeed, high
levels of HIF-1a transcription might compensate for decreases
in HIF-1a stability due to PHD2-mediated hydroxylation. Taken
together, these observations suggest that regulation of HIF-
mediated transcription that is conducive for hBM-MSC articu-
lar chondrogenesis is dependant more on 2-OG-mediated
mechanisms than those controlled by intracellular Fe21 levels.
Additionally, previous studies which demonstrate the depen-
dence of FIH on 2-OG availability and the ability of DMOG to
inhibit both PHD2 and FIH, suggest that DMOG’s potent effect
here may be via inhibition of both hydroxylases, whereas
CoCl2 and DFX may inhibit PHD2 only.
Figure 6. Inhibition of HIF-1a reduces the DMOG-mediated upregulation of a chondrogenic transcriptional profile. (A–C): Collagen Type
II immunofluorescence staining at day 14 of chondrogenesis. Scale bar5 400 lm (n5 4). Brightness and contrast were adjusted to an
equal degree between all conditions. (D): Quantification of Collagen Type II immunofluorescence at day 14 of chondrogenic induction,
normalized to equivalent DAPI-immunofluorescence (n5 4). Values are fold change compared with the no-treatment control represented
by the horizontal dotted line. Orange lines represent means for each condition. *p< .05 compared with 20%O2. (E–J): Gene expression
of VEGFA (E) and EGLN (F), SOX9 (G), COL2A1 (H), COL10A1 (I), and COL2A1/COL10A1 (J) at day 14 of chondrogenesis (n5 4) after treat-
ment with DMOG, 5%O2, DMOG1Acriflavine, or 5%O21Acriflavine. Values are fold change compared with the no-treatment condition
represented by the horizontal dotted line. Solid colored lines represent means for each condition. *p< .05 when compared with 20%O2,
and #p< .05 between 1/–ACF conditions within 20%O21DMOG or 5%O2 groups. Abbreviations: ACF, Acriflavine; DMOG,
dimethyloxalylglycine.
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The ability of DMOG to induce an expression profile that
is conducive for articular chondrogenesis, suggests its advan-
tage over CoCl2 and DFX for use in cartilage-regenerative ther-
apies. However, despite inducing expression of COL2A1 and
genes involved in post-translational modifications of collagen,
DMOG had a negative effect on cartilage-like ECM production.
We showed that this was partly mediated via HIF-1a, how-
ever, other mechanisms are likely involved as we were unable
to completely rescue cartilage-like ECM formation with Acrifla-
vine. DMOG has been shown to reduce the activity of prolyl-
4-hydroxylase, which is required for correct folding and poly-
merization of collagen fibrils [21]. Correspondingly, both FIH
and collagen prolyl hydroxylase (CP4HA1) have similar
affinities for 2-OG, as they have similar Km values for this co-
factor [47]. Therefore, FIH and P4HA1 are likely equally sensi-
tive to DMOG. This suggests that DMOG-mediated upregula-
tion of HIF target genes via FIH inhibition might be
accompanied by a similarly potent inhibition of collagen proc-
essing and incorporation into the ECM. Treatment with DMOG
for the final 7 days of induction restored the reduced levels
of Collagen Type II while upregulating expression of HIF target
and chondrogenic genes to similar levels we observed in
response to continuous treatment. This response could have
been mediated by a lack of continuous inhibition of the colla-
gen prolyl hydroxylase. Taken together, late DMOG treatment,
which can stimulate the formation of appropriate ECM, and
Figure 7. Late DMOG treatment does not inhibit the formation of a Collagen Type II-rich ECM but does induce a chondrogenic expres-
sion profile. (A–G): Collagen Type II immunofluorescence staining at day 21 of chondrogenesis after continuous (days 1–21) and late
(days 14–21) CoCl2, DFX and DMOG treatment (n5 4). Scale bar5 400 lm. Representative images from 4 independent repeats shown.
Brightness and contrast were adjusted for all channels to an equal degree between all conditions. (H): Quantification of Collagen Type II
immunofluorescence at day 21 of chondrogenic induction, normalized to equivalent DAPI-immunofluorescence (n5 4). Values are fold
change compared with the no-treatment control represented by the horizontal dotted line. The horizontal, colored lines represent
means for each condition. *, p< .05 compared with 20%O2. (I–L): Gene expression of SOX9 (I), P4HA1 (J), VEGFA (K), and EGLN (L) after
continuous (days 1–21) and late (days 14–21) CoCl2, DFX and DMOG treatment (n5 4). Values are normalized to the housekeeping gene
RPL13A and are fold change compared with the no-treatment control, represented by the horizontal dotted line. The horizontal colored
lines represent the means for each condition. *, p< .05 when compared with 20%O2. Abbreviations: CoCl2, cobalt chloride; DFX, desfer-
rioxamine, DMOG, dimethyloxalylglycine.
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induce mRNA expression of genes similarly to continuous
treatment, may be a valuable strategy for cartilage regenera-
tive medicine.
CONCLUSION
Hydroxylase inhibitors are potentially valuable in cartilage tis-
sue engineering strategies as they can mimic many of the
effects of hypoxia, providing important environmental cues to
progenitors, but without many of its potential drawbacks.
Here, we show that CoCl2, DFX, and DMOG treatment all
induced HIF-1a stabilization. However, unlike CoCl2 and DFX,
DMOG treatment strongly regulated HIF targets, and pro-
moted chondrocyte-specific gene expression. This suggests
that in hBM-MSC undergoing chondrogenic differentiation,
HIF-mediated changes in gene expression may rely more on
mechanisms that utilize 2-OG than those that rely on Fe21.
Our observations also suggest a role for DMOG in cartilage
tissue engineering strategies. For example, scaffolds that spa-
tially and/or temporally control the release of DMOG could
target the articular cartilage to aid in the repair of focal
defects. However, the maintenance of cartilage ECM in late
treatment-only conditions suggests the use of this 2-OG ana-
log would need to be optimized with regard to dosage/treat-
ment time. Alternatively, knowledge that DMOG inhibits both
FIH and PHD2 may suggest that dual and specific inhibition of
these hydroxylases during de novo cartilage formation may
result in HIF-mediated transcription that is conducive for artic-
ular chondrogenesis.
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